SCHEMBL18878172

SCHEMBL18878172

CNc1ccc(F)cc1OC(F)F

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.44
TSHR P16473 1/20 0.44
SMN1; SMN2 Q16637 4/20 0.40
HTT P42858 1/20 0.40
ALDH1A1 P00352 3/20 0.39
TTK P33981 1/20 0.38
KMT2A Q03164 4/20 0.37
GAA P10253 2/20 0.37
POLB P06746 1/20 0.37
LRRK2 Q5S007 1/20 0.36
MEN1 O00255 3/20 0.35
LMNA P02545 3/20 0.35
TP53 P04637 1/20 0.35
MAPK1 P28482 1/20 0.35
EIF4E P06730 2/20 0.34
MKNK1 Q9BUB5 2/20 0.34
MKNK2 Q9HBH9 2/20 0.34
ALOX12 P18054 1/20 0.33
APP P05067 1/20 0.33
PTGES2 Q9H7Z7 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28007720 0.85 ALDH1A1 (0.45) MAPTTSHRSMN1; SMN2HTTALDH1A1
SCHEMBL23033968 0.82 MKNK2 (0.35) MAPTTSHRPOLBEIF4EMKNK1
SCHEMBL19199502 0.81 ALDH1A1 (0.53) MAPTTSHRSMN1; SMN2HTTALDH1A1
SCHEMBL22838137 0.81 SMN1; SMN2 (0.40) MAPTTSHRSMN1; SMN2HTTALDH1A1
SCHEMBL18884312 0.81 SMN1; SMN2 (0.40) MAPTTSHRSMN1; SMN2HTTALDH1A1
SCHEMBL9230833 0.79 KMT2A (0.51) MAPTTSHRSMN1; SMN2HTTALDH1A1
SCHEMBL9232918 0.79 APP (0.51) MAPTSMN1; SMN2HTTALDH1A1KMT2A
SCHEMBL15508020 0.77 SMN1; SMN2 (0.40) MAPTTSHRSMN1; SMN2HTTALDH1A1
SCHEMBL22674295 0.77 APP (0.35) MAPTSMN1; SMN2HTTALDH1A1GAA
SCHEMBL31757623 0.76 ALDH1A1 (0.40) MAPTTSHRSMN1; SMN2HTTALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023154282-A1 COMPOUNDS HAVING A T-STRUCTURE FORMED BY AT LEAST FOUR CYCLES FOR USE IN THE TREATMENT OF CANCER AND OTHER INDICATIONS THERAS, INC. (US) 2023-08-17 WO disclosed
EP-3756464-A1 SUBSTITUTED OXADIAZOLES FOR COMBATING PHYTOPATHOGENIC FUNGI BASF SE (DE) 2020-12-30 EP disclosed
EP-3151669-B1 USE OF SUBSTITUTED OXADIAZOLES FOR COMBATING PHYTOPATHOGENIC FUNGI BASF SE (DE) 2020-10-28 EP disclosed
US-20170144980-A1 USE OF SUBSTITUTED OXADIAZOLES FOR COMBATING PHYTOPATHOGENIC FUNGI BASF SE (DE) 2017-05-25 US disclosed
US-20170144980-A1 USE OF SUBSTITUTED OXADIAZOLES FOR COMBATING PHYTOPATHOGENIC FUNGI BASF SE (DE) 2017-05-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170144980-A1 USE OF SUBSTITUTED OXADIAZOLES FOR COMBATING PHYTOPATHOGENIC FUNGI CYP51A1, DPM1, NOX1 MAPT 1939/4885TSHR 4784/4885SMN1; SMN2 3626/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.